GlaxoSmithKline and Tolerx, Inc. have formed a worldwide alliance to develop and commercialize otelixizumab (TRX4), a novel humanized anti-CD3 monoclonal antibody that has potential across a broad range of autoimmune and immune-mediated inflammatory diseases, including type 1 diabetes. Tolerx will have responsibility for the Phase III clinical program for type 1 diabetes in the U.S. as far as and including regulatory submission of the BLA. Tolerx has the option to co-promote otelixizumab in ...